Orbital metastasis: clinical features, management and outcome.
OBJECTIVE
To review the clinical features, treatment, outcome and survival of metastatic tumors of the orbit.


METHODS
Retrospective, non-comparative, chart review of 80 patients with orbital metastasis treated in four tertiary orbital centres in Australia.


RESULTS
The study included 80 patients of which, 44 were male with a mean age of 60 years. Orbital involvement commonly presented late in a multisystemic disease; however, the orbit was the first presentation in 15% of the cases. Diplopia (48%), pain (42%), and visual loss (30%) were the commonest symptoms at presentation; whereas proptosis (63%), strabismus (62%), and visual loss (41%) were the most frequent clinical signs. Computed tomography commonly showed a solid enhancing mass (42 cases) located within the orbital fat (43%), or enlarging an extraocular muscle (28%). Breast carcinoma (29%), melanoma (20%), and prostatic cancer (13%) were the most frequent histological types. Treatment was often multi-disciplinary and modalities included radiotherapy, chemotherapy, hormone therapy, surgery, and immunotherapy. Survival was limited to 1.5 years after diagnosis independent of the histological type, with 29% of patients alive after 17 months follow-up.


CONCLUSIONS
A high index of suspicion and appropriate intervention with histological diagnosis can help in the management and quality of life in patients with metastatic orbital disease. Overall survival is limited and we encountered statistical limitations proving differences in the survival based on the sub-type of primary tumour involved. Metastatic orbital melanoma presented a higher incidence when compared with previous studies, probably due to the increase frequency of skin found in the Australian population.
Orbital, Lacrimal and Oculoplastic Clinic, Department of Ophthalmology & Visual Sciences, QEII Health Sciences Centre, Dalhousie University, Halifax, Canada. AA.Valenzuela@dal.ca
Alejandra A
AA
Valenzuela
Curtis W
CW
Archibald
Ben
B
Fleming
Lorraine
L
Ong
Brett
B
O'Donnell
John
J
Crompton J
Dinesh
D
Selva
Alan A
AA
McNab
Timothy J
TJ
Sullivan
D000293:Adolescent; D000328:Adult; D000367:Age Factors; D000368:Aged; D000369:Aged, 80 and over; D001315:Australia; D044963:Biopsy, Fine-Needle; D002423:Cause of Death; D017024:Chemotherapy, Adjuvant; D002648:Child; D002675:Child, Preschool; D015331:Cohort Studies; D003131:Combined Modality Therapy; D016001:Confidence Intervals; D005260:Female; D006801:Humans; D007150:Immunohistochemistry; D007167:Immunotherapy; D007223:Infant; D053208:Kaplan-Meier Estimate; D008297:Male; D008875:Middle Aged; D009367:Neoplasm Staging; D009918:Orbital Neoplasms / Q000175:diagnosis / Q000401:mortality / Q000473:pathology / Q000556:secondary* / Q000628:therapy*; D018714:Radiotherapy, Adjuvant; D012189:Retrospective Studies; D018570:Risk Assessment; D012737:Sex Factors; D016019:Survival Analysis; D016896:Treatment Outcome; D055815:Young Adult